Loading…
Major Korean vaccine and plasma-derived (blood-product) pharma company, a leading domestic vaccine manufacturer.
Major Korean vaccine and plasma-derived (blood-product) pharma company, a leading domestic vaccine manufacturer.
Sells vaccines largely to Korea's national immunisation programme and the private market, and plasma drugs such as immunoglobulin at home and abroad, so government purchasing and the supply of donor plasma, a scarce input, drive results. Its immunoglobulin Alyglo won US FDA approval in late 2023 and began US sales in 2024.
Moat: narrow (regulatory licence, scale, process know-how). One of few Korean makers with both vaccine and plasma-fractionation manufacturing licenses.
Headquarters: Yongin, South Korea · Founded: 1967 · Employees: 2,351
Size GC Biopharma (006280.KS) is a South Korea Health Care company (Pharmaceuticals: Major) with a market value of $1.18B, the 215th largest of 495 South Korea companies the cockpit tracks. Shares closed at ₩140,100 on 6 Nov 2026.
Performance Over six months the shares gained 2.2%, against -8.1% for the median peer and -24.5% for the South Korea market (cap-weighted) — 8th highest of 21 in its peer set.
Growth Revenue fell 3.0% over the last twelve months (peer median 0.0%); the operating margin is 3.6% (peer median 10.6%).
Valuation It trades at 5.0× forward earnings against a peer median of 19.6× (cheapest of 14).
Price implies For today's price to make sense, revenue must grow about 8% a year for seven years (Req g). Recent delivered growth is +6%, so the hurdle is +2 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 1.6 points below its cost of capital (5.1% WACC).
Next results Next results expected around 23 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ₩1.88T | ₩1.99T | ₩1.68T | ₩1.63T | ₩1.71T |
| Revenue growth | — | +19% | +3% | -5% | — |
| Gross profit | n/a | ₩536B | ₩468B | ₩459B | ₩561B |
| EBITDA | n/a | ₩155B | ₩113B | ₩110B | ₩146B |
| Net income | ₩143B | -₩4.67B | -₩26.3B | -₩26.6B | ₩65.5B |
| Free cash flow | n/a | ₩27.1B | -₩85.5B | -₩84.6B | ₩61.2B |
| Capital expenditure | n/a | ₩105B | ₩42.4B | ₩126B | ₩94.7B |
| Total debt | n/a | ₩982B | ₩828B | ₩724B | ₩576B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| GC Biopharma 006280.KS | $1.18B | +2% | -3% | 4% | 5.0× | 8.3% |
| SKBS 302440.KS | $2.22B | -11% | +23% | -25% | n/a | n/a |
| CSL CSL.AX | $67.2B | +105% | -2% | 26% | 22.4× | 7.1% |
| Grifols GRF.MC | $7.49B | +23% | 0% | 16% | 13.0× | 6.8% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 006280.KS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +7.4% | -2.2% | 7th highest of 21 |
| 6-month return | +2.2% | -8.1% | 8th highest of 21 |
| Distance from 52-week high | -23.0% | -31.2% | 8th highest of 21 |
| Revenue growth (TTM) | -3.0% | 0.0% | 8th lowest of 19 |
| Operating margin | 3.6% | 10.6% | 8th lowest of 20 |
| Forward P/E | 5.0× | 19.6× | cheapest of 14 |
| Growth the price implies (Req g, 7 yrs) | 8.3% | 3.3% | 4th most demanding of 13 |
| Growth delivered (Del g) | +5.8% | +8.9% | 6th lowest of 13 |
| Hurdle (Req g minus delivered) | +2.5 pp | -3.2 pp | 6th most demanding of 13 |
| ROIC minus cost of capital | -1.6 pp | -0.1 pp | 7th lowest of 19 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| GC Biopharma 006280.KS | South Korea | $1.18B | +2% | -3% | 4% | 5.0× | 8.3% | +5.8% |
| Tianjin Ringpu Bio-technology 300119.SZ | China | $1.18B | -4% | -9% | 11% | 19.6× | 5.8% | +11.3% |
| Vetoquinol VETO.PA | France | $1.17B | +22% | -1% | 15% | 15.8× | -3.0% | +4.2% |
| Cosmo CMHC.SW | Switzerland | $1.17B | -25% | -45% | -13% | 432.6× | n/a | n/a |
| Shanghai InnoStar Bio-tech 688710.SS | China | $1.17B | +28% | +24% | 6% | 85.2× | 16.2% | +19.4% |
| North China Pharmaceutical 600812.SS | China | $1.17B | -8% | -21% | 5% | n/a | 1.4% | -4.2% |
| InventisBio 688382.SS | China | $1.19B | -41% | -61% | -563% | n/a | 10.4% | -60.6% |
| Jiuzhitang 000989.SZ | China | $1.19B | -13% | +46% | 19% | 22.7× | -3.7% | -9.0% |
| Seaport Therapeutics SPTX | United States | $1.15B | +34% | n/a | n/a | n/a | n/a | n/a |
| MedinCell MEDCL.PA | France | $1.15B | -1% | -23% | -131% | n/a | n/a | n/a |
| Changzhou Qianhong Bio-Pharma 002550.SZ | China | $1.21B | -8% | -2% | 15% | 19.6× | 4.5% | -1.2% |
| Amphastar Pharmaceuticals AMPH | United States | $1.21B | +50% | +1% | 16% | 8.9× | 3.3% | +15.5% |
| Everest Medicines 1952.HK | Hong Kong | $1.22B | -20% | +193% | -5% | 26.9× | n/a | n/a |
| Shanghai Yizhong Pharmaceutical 688091.SS | China | $1.13B | -34% | +32% | 14% | n/a | n/a | n/a |
| Aurisco Pharmaceutical 605116.SS | China | $1.13B | -18% | +9% | 28% | 15.4× | 1.5% | +18.7% |
| Omeros OMER | United States | $1.22B | +14% | n/a | -190% | 7.7× | n/a | n/a |
| Zhejiang Jolly Pharmaceutical 300181.SZ | China | $1.13B | -18% | +17% | 20% | 12.8× | 1.1% | +22.8% |
| ST Pharm 237690.KS | South Korea | $1.12B | -52% | +26% | 18% | 27.9× | n/a | n/a |
| Shandong Lukang Pharmaceutical 600789.SS | China | $1.11B | -13% | -7% | 3% | n/a | 3.3% | +6.5% |
| Blue Jet Healthcare BLUEJET.NS | India | $1.11B | +13% | -28% | 28% | 32.5× | 49.0% | +13.8% |
| MannKind MNKD | United States | $1.25B | +11% | +30% | 3% | n/a | n/a | n/a |